Japan Tissue Engineering Co., Ltd. (JP:7774)
:7774
7774 Stock Chart & Stats
¥575.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥575.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥390.00 - ¥883.00
Previous CloseN/A
Volume17.40K
Average Volume (3M)51.90K
Market Cap
¥25.42B
Enterprise Value¥21.60B
Total Cash (Recent Filing)¥3.92B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.17
Next Earnings
May 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.56
Shares Outstanding40,610,200
10 Day Avg. Volume45,190
30 Day Avg. Volume51,896
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)3.19
Price to Sales (P/S)7.56
P/FCF Ratio-82.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.9
Revenue Forecast (FY)¥5.05B
Bulls Say, Bears Say
Bulls Say
Low-debt Balance SheetA near-zero debt profile provides durable financial flexibility to fund R&D, scale manufacturing and absorb periodic cash burn without heavy interest burden. This reduces solvency risk and supports longer-term investment in regulatory and commercial milestones.
Strong Revenue RecoverySustained double-digit and then very strong year-over-year revenue growth signals product traction and expanding commercial adoption. Durable top-line expansion underpins scale economics for manufacturing and service revenue, improving long-term operating leverage if costs are controlled.
High Gross MarginsConsistently high gross margins reflect valuable proprietary cell-processing and product differentiation in regenerative medicine. Margin-rich core products create capacity to invest in R&D, reimbursement efforts and manufacturing scale while preserving the potential for eventual sustainable profitability.
Bears Say
Negative Operating Cash FlowRecurring negative operating and free cash flow indicates the business is not yet self-funding; it increases reliance on external capital despite low debt. Over months this raises dilution and funding-risk sensitivity if revenue or margins falter during scale-up phases.
Volatile ProfitabilitySwinging from modest profit to material loss shows earnings are highly sensitive to operating costs and execution. Persistent margin volatility undermines confidence in sustainable returns and complicates multi-period planning for capacity, hiring, and commercial expansion.
Execution Sensitivity To Scaling & RegulationGrowth depends on complex manufacturing scale-up, regulatory compliance and securing reimbursement. These structural execution and regulatory hurdles can delay commercialization, raise costs, and amplify cash burn over 2–6 months as the company grows product volumes and service contracts.
Japan Tissue Engineering Co., Ltd. News
7774 FAQ
What was Japan Tissue Engineering Co., Ltd.’s price range in the past 12 months?
Japan Tissue Engineering Co., Ltd. lowest stock price was ¥390.00 and its highest was ¥883.00 in the past 12 months.
What is Japan Tissue Engineering Co., Ltd.’s market cap?
Japan Tissue Engineering Co., Ltd.’s market cap is ¥25.42B.
When is Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date?
Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date is May 01, 2026 which is in 22 days.
How were Japan Tissue Engineering Co., Ltd.’s earnings last quarter?
Japan Tissue Engineering Co., Ltd. released its earnings results on Jan 30, 2026. The company reported -¥4.56 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.56.
Is Japan Tissue Engineering Co., Ltd. overvalued?
According to Wall Street analysts Japan Tissue Engineering Co., Ltd.’s price is currently Overvalued.
Does Japan Tissue Engineering Co., Ltd. pay dividends?
Japan Tissue Engineering Co., Ltd. does not currently pay dividends.
What is Japan Tissue Engineering Co., Ltd.’s EPS estimate?
Japan Tissue Engineering Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Japan Tissue Engineering Co., Ltd. have?
Japan Tissue Engineering Co., Ltd. has 40,610,200 shares outstanding.
What happened to Japan Tissue Engineering Co., Ltd.’s price movement after its last earnings report?
Japan Tissue Engineering Co., Ltd. reported an EPS of -¥4.56 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.255%.
Which hedge fund is a major shareholder of Japan Tissue Engineering Co., Ltd.?
Currently, no hedge funds are holding shares in JP:7774
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. is a subsidiary of Teijin Limited.